logo Kompas.id
EnglishLooking into the Nusantara Vaccine

Looking into the Nusantara Vaccine

All fields have a specific domain. Vaccines are the domain of medicine and health, so let the professionals in this field make the decisions.

Oleh IQBAL MOCHTAR
· 1 menit baca

The locally developed Nusantara vaccine candidate has suddenly become a controversial issue.

It started out simply. A team led by former health minister Agus Terawan is currently conducting local trials on a dendritic cell-based Covid-19 vaccine. The team has entered phase 2 trials, which is being carried out on a limited number of volunteers. Several parties have claimed this vaccine as “the work of the nation’s children” (homegrown).

Perhaps they are claiming it as a homegrown vaccine because it is called “Nusantara” (archipelago), another name for Indonesia. Due in part because of its name, several parties have expressed their support for the vaccine, including a number of public figures. Their support has been widely published in newspapers and on social media. Several House of Representatives (DPR) lawmakers have also volunteered for the trials. The reason is nationalism: locally developed products must be fully supported. The support has continued to flow.

banner registration
Lanjutkan baca artikel ini dan artikel lainnya dengan daftar akun Kompas.id.
Jadilah Bagian dari Jurnalisme Berkualitas Dapatkan akses tanpa batas ke seluruh artikel premium dengan berlangganan Kompas.id.
Kompas Digital Premium 12 Bulan (Hemat 40%)
Kompas Digital Premium 12 Bulan (Hemat 40%)
Rp 360.000 /Tahun
BERLANGGANAN
Akses tak terbatas Kompas.id (web & app)
Berita digital tanpa iklan pop-up
30 arsip terbaru ePaper Kompas
Artikel Opini eksklusif
Multiplatform, akses Kompas.id melalui laptop, ponsel, ataupun tablet
Hemat 40%
POPULER
Kompas Digital Premium 1 Bulan
Kompas Digital Premium 1 Bulan
Rp 50.000 /Bulan
BERLANGGANAN
atau biarkan Google mengelola langganan Anda untuk paket ini:
Akses tak terbatas Kompas.id (web & app)
Berita digital tanpa iklan pop-up
30 arsip terbaru ePaper Kompas
Artikel Opini eksklusif
Multiplatform, akses Kompas.id melalui laptop, ponsel, ataupun tablet
Kompas Digital Premium & Koran
Kompas Digital Premium & Koran
Rp 108.000 /Bulan
BERLANGGANAN
Akses tak terbatas di Kompas.id (web & app)
Berita digital tanpa iklan pop-up
30 arsip terbaru ePaper Kompas
Artikel Opini eksklusif
Multiplatform, akses Kompas.id melalui laptop, ponsel, ataupun tablet
Pengiriman koran Kompas edisi cetak ke rumah Anda
Editor: Syahnan Rangkuti
Bagikan
Memuat data..